Investment Promotion in Shanghai: TEDA Biopharmaceutical Cooperation and Exchange Conference Held in Shanghai

On the afternoon of December 16th, the "Development Strategy in China for Pharma and Medical Devices Multinationals——Exchange Conference on Tianjin Local Policies Interpretation, M&A and Cooperative Innovation ," jointly organized by the American Chamber of Commerce in Shanghai and the TEDA Administrative Commission, was held in Shanghai. Through policy interpretations on biopharmaceuticals, regional comprehensive presentations, case studies from multinational corporations, and on-site networking exchanges, the conference aimed to help foreign-invested enterprises accurately grasp policy directions, seize market opportunities, and collaborate with TEDA to promote high-quality development in the biopharmaceutical industry. Representatives from over 60 multinational corporations and institutions, including Medtronic, Danaher, Roche Diagnostics, GE Healthcare Financial Services, Sekisui Medical, and Kenvue , attended the event.

Zhang Shengxi, Deputy Director-General of the Tianjin Medical Products Administration, attended the event and delivered a speech. He provided a systematic overview of the development trends in Tianjin’s biomedical industry and introduced innovative policies and measures implemented by the city to support the growth of the biomedical sector, citing specific case studies. Zhang emphasized that Tianjin, as one of the first national bio-industry bases in China, boasts a solid industrial foundation and a favorable innovation ecosystem. He extended a warm welcome to domestic and international enterprises to invest and establish operations in Tianjin, working together to advance the thriving development of the biomedical industry.

Jin Xianghua, Vice Chairwoman of the TEDA Administrative Commission, attended the event and delivered a speech. She noted that as one of the first national-level development zones in China, TEDA has built a modern industrial system with an industrial output value exceeding 500 billion yuan, attracting a total of 601 investment projects from 124 Fortune 500 multinational companies. In the pharmaceutical and medical device sector, the region has gathered leading enterprises such as Novo Nordisk, Servier, Asymchem, WuXi AppTec, and Sinomed, along with a number of high-level innovation and incubation platforms, forming a complete industrial chain from R&D innovation and clinical translation to manufacturing and supply chain support. Jin Xianghua emphasized that all participating enterprises have demonstrated outstanding performance in their respective fields, and expressed hope that this exchange conference would serve as an opportunity to engage in deeper cooperation with global biopharmaceutical companies in areas such as innovative R&D, achievement commercialization, and market expansion, thereby achieving mutual benefit and win–win outcomes.

According to a representative of AMCHAM SHANGHAI, this conference focused on policy interpretation, industry practices, and practical exchanges. It brought together guests from regulatory agencies, industrial parks, and the corporate sector, providing a platform for in-depth communication and enhanced collaboration among all parties.

During the meeting, relevant officials from the Tianjin Medical Products Administration provided authoritative interpretations of the domestic segmented production policies for multinational pharmaceutical companies and the service policies for medical device enterprises. Representatives from the Tianjin Medical Device Evaluation and Inspection Center highlighted the medical device registration policies and review processes in Tianjin. Officials from the TEDA Pharmaceutical and Healthcare Bureau elaborated on the advantages of TEDA's biomedical industry and its business environment.

In the corporate sharing session, Lan Jun, General Manager of Tianjin Bonna-Agela Technologies Co., Ltd. under the Danaher Group, shared the company's practical experience in mergers and acquisitions integration in China and accelerating the development of localized capabilities. He emphasized the strategic considerations behind establishing a global R&D, innovation, and manufacturing base in TEDA and expressed strong confidence in deepening roots in TEDA  and expanding the Chinese market. On the other hand, Huang Wenjie, Head of Corporate and Government Affairs at UCB China, shared the company's exploration in building an innovation ecosystem by collaborating with local R&D institutions, biotech companies, universities, and other stakeholders. The company has established a long-term cooperation mechanism with TEDA in R&D collaboration and industry-academia-research linkage, serving as a model for government-enterprise collaborative innovation.

This exchange conference marks the first meeting held after the upgrade of TEDA’s Shanghai Office to the TEDA Yangtze River Delta Industrial Empowerment and Coordination Center. The center is a thoughtfully designed, multifunctional space that integrates exhibition, communication, and event hosting, tailored to meet the current practical needs of investment promotion in the Yangtze River Delta region. It aims to enhance regional promotion and empower targeted investment attraction. The exchange conference established an efficient and practical platform for communication between TEDA and multinational biopharmaceutical enterprises, effectively showcasing TEDA and Tianjin’s biopharmaceutical industry and development opportunities, thereby boosting multinational companies’ confidence in investing in Tianjin. During the event, several multinational companies engaged in in-depth discussions with TEDA’s investment promotion team and expressed their willingness to explore further cooperation. In the future, TEDA will continue to optimize its innovation ecosystem, enhance service efficiency, promote the innovative development of the biopharmaceutical industry, and provide a broader development platform for global enterprises.